Search

Here, we report preliminary safety and efficacy data from a phase II study evaluating capivasertib in pts with R/R B-NHL (NCT05008055). Several PI3K inhibitors (PI3Ki) have been approved to treat relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL). B Introduction: b The PI3K/AKT/mTOR pathway is an established therapeutic target in indolent B-cell non-Hodgkin lymphoma (B-NHL). [Extracted from the article]

Transfusion needs may impact patients' quality of life and CAR T-cells efficacy through transfusion-related immunomodulation. Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. B Introduction: b Patients undergoing CAR T-cell therapy may experience severe cytopenias due to lymphodepleting chemotherapy and/or CAR T-cells. [Extracted from the article]

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1-3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM-2 Encore Abstract - previously submitted to EHA 2023 The research was funded by: Regeneron Pharmaceuticals, Inc. Keywords: immunotherapy, indolent non-Hodgkin lymphoma B Conflicts of interests pertinent to the abstract b B S. Novelli b Consultant or advisory role: Mundipharma Research funding: Novartis B S. Luminari b Consultant or advisory role: Roche, Kite, BMS, Janssen Other remuneration: Speakers Bureau fees for BMS and Janssen B M. Taszner b Consultant or advisory role: Roche, Takeda Honoraria: Roche, Takeda, Novartis, Servier Educational grants: Roche B S. Le Gouill b Consultant or advisory role: Novartis, Kite/Gilead, Janssen Honoraria: Novartis, Kite/Gilead, Janssen Educational grants: Novartis, Kite/Gilead, Janssen B R. Champion b Other remuneration: Speaker bureau fees from AbbVie and BMS B E. Bachy b Consultant or advisory role: Roche, Gilead, ADC Therapeutics, Takeda, Novartis, Incyte Honoraria: Kite, Gilead, Novartis, Roche, Incyte, Miltenyi Biotech, Takeda, Sanofi Research funding: Amgen, BMS B S. Guidez b Honoraria: Gilead/Kite, Takeda, Incyte, AstraZeneca B A. Alonso b Consultant or advisory role: Abbvie, Janssen, Incyte, GlaxoSmithKline Honoraria: Abbvie, Janssen, Incyte, GlaxoSmithKline. B Introduction: b Odronextamab is a CD20 × CD3 bispecific antibody (Ab). [Extracted from the article]

B Introduction: b The primary analysis of the Ro-CHOP trial ( I NCT01796002 i ) demonstrated that romidepsine (Ro) plus CHOP did not provide an increased efficacy compared with CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL). ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: FINAL ANALYSIS OF THE RO-CHOP TRIAL B Methods: b The study was an open-label multicenter randomized (1:1) phase III study of Ro-CHOP versus CHOP as frontline treatment of patients 18-80 years with PTCL. [Extracted from the article]

This study aims to provide QoL level for DLBCL patients at diagnosis and after 1 year, and to assess the occurrence of a RS effect. B Introduction: b Few quality of life (QoL) data are available for diffuse large B-cell lymphoma (DLBCL) patients during the first year of diagnosis. Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis. [Extracted from the article]

Aims: To provide real-life data on patterns of use and safety of ibrutinib., Methods: A cohort study including all patients initiating ibrutinib between 21 November 2014 and 21 November 2018, and followed for 1 year was conducted. Patient characteristics, ibrutinib use and adverse drug reactions (ADRs) were collected from medical records. Kaplan-Meier analysis estimated the probability of developing ibrutinib-associated serious ADRs (SADRs) with a 95% confidence interval (CI). A Cox proportional hazards model was used to investigate factors associated with SADR occurrence., Results: In total, 102 patients were included in the study. The median age was 70.3 years (interquartile range 64.7-75.6), the male/female gender ratio was 2.9. Almost half the patients (47.1%) were prescribed ibrutinib for chronic lymphocytic leukaemia (CLL). Forty-three patients (42.1%) permanently discontinued ibrutinib in the first year, mostly for progression (51.2%) or ADRs (32.6%). Forty-eight patients (47.1%) experienced at least one ibrutinib-associated SADR. Haematological, infectious and vascular disorders were the most frequent SADRs. The probability of developing ibrutinib-associated SADR was 35.1% (95% CI 26.3-45.7%) at 3 months, 44.8% (35.2%; 55.8%) at 6 months and 54.3% (44.0%; 65.2%) at 12 months. Age ≥80 years (hazard ratio [HR] 2.03; 95% CI 1.02-4.05) and CLL (HR 1.81; 95% CI 1.01-3.25) were significantly associated with a higher risk of SADR occurrence., Conclusion: This study found a high cumulative incidence of ibrutinib-associated SADRs within the first year of treatment. In view of the risk of SADR, patients aged ≥80 years or treated for CLL deserve special attention., (© 2020 The British Pharmacological Society.)

Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine-based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B-cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m 2 /day (50-250) on days-7 and -6. The observed grade 1-4 toxicities included mucositis (83.5%), gastroenteritis (53%), skin toxicity (34%), colitis (29%), liver toxicity (19%), pneumonitis (5%), and cardiac rhythm disorders (4%). Nonrelapse mortality (NRM) was reported in 3.3% of patients. Acute renal failure (ARF) was reported in 132 cases (27.9%) (G ≥2; 12.3%). Organ toxicities and death were more frequent in patients with post conditioning renal failure. In a multivariate analysis, pretransplant chronic renal failure, bendamustine dose >160 mg/m 2 and age were independent prognostic factors for ARF. Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM. A simple, four-point scoring system can stratify patients by levels of risk for ARF and may allow for a reduction in the bendamustine dose to avoid toxicity. Drugs shortage may have dangerous consequences. Prospective, comparative studies are needed to confirm the toxicity/efficacy extents from this conditioning regimen compared to other types of high dose therapy., (© 2018 Wiley Periodicals, Inc.)

Lenalidomide is manageable and effective in multiple myeloma, particularly in elderly patients. Surprisingly, the combination of lenalidomide with rituximab produced clinically significant anemia at 25 mg/day for 21/28 days, the highest possible dose, in Waldenström's Macroglobulinemia (WM). We aimed to determine the maximum tolerated dose (MTD) of single agent lenalidomide and determine its impact on WM. RV-WM-0426 is a multicenter dose escalation open label phase 1/2 study of lenalidomide in relapsed/refractory WM (RRWM). Lenalidomide was given orally 21/28 days per cycle for 1 year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD. Seventeen RRWM patients were included. The MTD was established at 15 mg/day 21/28. By ITT analysis, the overall response rate was 29%. With a median follow-up of 36 months, median TTP was 16 months (95% CI 5.5-26), the 5-year OS was 91%. The most frequent adverse events ≥ grade 3 at 15 mg were 14% anemia and 43% neutropenia. The MTD of lenalidomide is 15 mg/day 21/28 days in RRWM. Lenalidomide is active in the treatment of RRWM and the safety profile appears manageable. Future studies may look into combinations of lenalidomide and continuous dosing., (© 2015 Wiley Periodicals, Inc.)